SRPTSarepta Therapeutics, Inc.
Dec 10, 2026 — Competitor Data Readouts & Pricing Policy Scrutiny
Chart by TradingViewThe schedule
- Thu10Dec
Pricing scrutiny and competitor gene-therapy data pose significant systemic overhangs.
- Mon11Jan
The J.P. Morgan conference offers management a platform to re-establish the FY2027 growth narrative.
- Wed3Feb
Q3 results will be heavily scrutinized for commercial traction and operating leverage.
- Wed5May
Q4 earnings will serve to validate or dismantle the previously issued conference guidance.
- Wed4Aug
The initial quarter of 2027 will demonstrate whether the newly set trajectory is sustainable.
- Wed3Nov
Past
- Tue6Oct
Pipeline updates at major conferences typically favor Sarepta's gene therapy narrative, potentially driving a rebound.
- Wed5Aug
With shares pushing to $19.28 and technically overbought, expectations are elevated heading into the print.
- Mon1Jun
Actual outcome: Bull · $18.20 at outcome
